Rheumatology.net

Rheumatology Xagena

Xagena Mappa
Medical Meeting
XagenaNewsletter
Reumabase.it

Search results for "Behçet’s disease"

Celgene has announced results of phase II trial ( BCT-001 ) on Apremilast, a oral targeted inhibitor of phosphodiesterase 4 ( PDE4 ), in patients with Behçet’s disease.These data have showed that sign ...